{"id":13320,"date":"2018-05-04T10:46:37","date_gmt":"2018-05-04T08:46:37","guid":{"rendered":"https:\/\/news.embl.de\/?p=13320"},"modified":"2024-03-22T23:13:54","modified_gmt":"2024-03-22T22:13:54","slug":"celgene-joins-open-targets","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/","title":{"rendered":"Celgene joins Open Targets"},"content":{"rendered":"\n<p>Today,&nbsp;<a href=\"http:\/\/www.celgene.co.uk\/\" target=\"_blank\" rel=\"noopener noreferrer\">Celgene<\/a> has joined <a href=\"https:\/\/www.opentargets.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Open Targets<\/a>, expanding its collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets. Celgene is a global biopharmaceutical company with expertise in the discovery and development of innovative therapies for cancer, immune-inflammatory, etc.<\/p>\n\n\n\n<p>Celgene\u2019s expertise will enhance the offerings of the current Open Targets collaborators <a href=\"http:\/\/www.ebi.ac.uk\" target=\"_blank\" rel=\"noopener noreferrer\">European Bioinformatics Institute (EMBL-EBI)<\/a>, <a href=\"https:\/\/www.gsk.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">GSK<\/a>, <a href=\"https:\/\/www.biogen.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Biogen<\/a>, <a href=\"https:\/\/news.embl.de\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/\" target=\"_blank\" rel=\"noopener noreferrer\">Takeda<\/a>, the <a href=\"http:\/\/www.sanger.ac.uk\/\" target=\"_blank\" rel=\"noopener noreferrer\">Wellcome Sanger Institute<\/a>.<\/p>\n\n\n\n<p>Open Targets is a unique, precompetitive public-private consortium.&nbsp; It was founded by the EMBL-EBI, GSK and the Wellcome Sanger Institute in 2014. The aim is to systematically improve the identification and prioritisation of drug targets, leading to safe and effective medicines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Academic and industrial expertise<\/h2>\n\n\n\n<p>\u201cThe combination of academic and industrial expertise, focused on the huge challenge of high quality drug target identification and prioritisation makes Open Targets a unique consortium,\u201d says <a href=\"https:\/\/www.ebi.ac.uk\/about\/people\/rolf-apweiler\" target=\"_blank\" rel=\"noopener noreferrer\">Rolf Apweiler, EMBL-EBI Director and Interim Head of Open Targets<\/a>. \u201cWe are excited about bringing Celgene\u2019s insight and expertise to the consortium and pursuing research together. Most importantly, we look forward to sharing our methods and results openly with the research community.\u201d<\/p>\n\n\n\n<p>The freely available <a href=\"http:\/\/www.targetvalidation.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Open Targets Platform<\/a> provides a user-friendly web interface for researchers working in many disciplines to investigate causal links between genes and diseases, and to identify and prioritise therapeutic targets for new medicines.<\/p>\n\n\n\n<p>A longer version of this post was originally published on <a href=\"https:\/\/www.ebi.ac.uk\/about\/news\/press-releases\/celgene-joins-open-targets\" target=\"_blank\" rel=\"canonical nofollow noopener noreferrer\" data-href=\"insert original\">EMBL-EBI News.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New partner strengthens drug discovery collaboration<\/p>\n","protected":false},"author":47,"featured_media":13323,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17595,3],"tags":[28,312,36,71],"embl_taxonomy":[],"class_list":["post-13320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-connections","category-lab-matters","tag-bioinformatics","tag-drug-discovery","tag-embl-ebi","tag-industry"],"acf":{"article_intro":"<p>Celgene has joined Open Targets, the\u00a0public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.<\/p>\n","related_links":[{"link_description":"Open Targets Platform","link_url":"http:\/\/www.targetvalidation.org\/"},{"link_description":"Takeda joins drug target discovery initiative","link_url":"https:\/\/news.embl.de\/lab-matters\/takeda-joins-open-targets-drug-target-discovery-initiative\/"}],"article_sources":false,"vf_locked":false,"featured":false,"color":"#007B53"},"embl_taxonomy_terms":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Celgene joins Open Targets<\/title>\n<meta name=\"description\" content=\"Celgene joins Open Targets, expanding the collaboration&#039;s collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celgene joins Open Targets\" \/>\n<meta property=\"og:description\" content=\"Celgene joins Open Targets, expanding the collaboration&#039;s collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-04T08:46:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T22:13:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"425\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oana Stroe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Oana Stroe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\"},\"author\":{\"name\":\"Oana Stroe\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\"},\"headline\":\"Celgene joins Open Targets\",\"datePublished\":\"2018-05-04T08:46:37+00:00\",\"dateModified\":\"2024-03-22T22:13:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\"},\"wordCount\":234,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg\",\"keywords\":[\"bioinformatics\",\"drug discovery\",\"embl-ebi\",\"industry\"],\"articleSection\":[\"Connections\",\"Lab Matters\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\",\"url\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\",\"name\":\"Celgene joins Open Targets\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg\",\"datePublished\":\"2018-05-04T08:46:37+00:00\",\"dateModified\":\"2024-03-22T22:13:54+00:00\",\"description\":\"Celgene joins Open Targets, expanding the collaboration's collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg\",\"width\":620,\"height\":425,\"caption\":\"Celgene joins public-private drug target discovery initiative Open Targets. PHOTO: Celgene\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414\",\"name\":\"Oana Stroe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g\",\"caption\":\"Oana Stroe\"},\"description\":\"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.\",\"url\":\"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celgene joins Open Targets","description":"Celgene joins Open Targets, expanding the collaboration's collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/","og_locale":"en_US","og_type":"article","og_title":"Celgene joins Open Targets","og_description":"Celgene joins Open Targets, expanding the collaboration's collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets.","og_url":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2018-05-04T08:46:37+00:00","article_modified_time":"2024-03-22T22:13:54+00:00","og_image":[{"width":620,"height":425,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","type":"image\/jpeg"}],"author":"Oana Stroe","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Oana Stroe","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/"},"author":{"name":"Oana Stroe","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414"},"headline":"Celgene joins Open Targets","datePublished":"2018-05-04T08:46:37+00:00","dateModified":"2024-03-22T22:13:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/"},"wordCount":234,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","keywords":["bioinformatics","drug discovery","embl-ebi","industry"],"articleSection":["Connections","Lab Matters"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/","url":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/","name":"Celgene joins Open Targets","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","datePublished":"2018-05-04T08:46:37+00:00","dateModified":"2024-03-22T22:13:54+00:00","description":"Celgene joins Open Targets, expanding the collaboration's collective efforts to transform drug discovery through the systematic identification and prioritisation of drug targets.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/lab-matters\/celgene-joins-open-targets\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","width":620,"height":425,"caption":"Celgene joins public-private drug target discovery initiative Open Targets. PHOTO: Celgene"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/95d28f359cc138357c5dcf79319ef414","name":"Oana Stroe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/105fb83bbeaf64062ef1f4608964e5163ac52f590628df2ffde6de9a0d85af80?s=96&d=mm&r=g","caption":"Oana Stroe"},"description":"Oana Stroe is a PR specialist and copywriter with experience in engineering, IT and life sciences. She now collects and shares remarkable science stories.","url":"https:\/\/www.embl.org\/news\/author\/oana-stroe-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-3\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2018\/05\/Celgene_joins_Open_Targets_EMBL_620x425.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/13320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=13320"}],"version-history":[{"count":6,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/13320\/revisions"}],"predecessor-version":[{"id":21903,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/13320\/revisions\/21903"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/13323"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=13320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=13320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=13320"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=13320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}